These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 27190384)

  • 1. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
    Opelz G; Unterrainer C; Süsal C; Döhler B
    Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
    Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
    Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
    [No Abstract]   [Full Text] [Related]  

  • 3. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
    Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
    Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial skin cancers after kidney transplantation: a retrospective single-centre study of 376 recipients.
    Kaufmann RA; Oberholzer PA; Cazzaniga S; Hunger RE
    Eur J Dermatol; 2016 Jun; 26(3):265-70. PubMed ID: 26985913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.
    Badve SV; Pascoe EM; Burke M; Clayton PA; Campbell SB; Hawley CM; Lim WH; McDonald SP; Wong G; Johnson DW
    Clin J Am Soc Nephrol; 2016 Oct; 11(10):1845-1855. PubMed ID: 27445164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
    Klintmalm GB; Saab S; Hong JC; Nashan B
    Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich.
    Wimmer CD; Rentsch M; Crispin A; Illner WD; Arbogast H; Graeb C; Jauch KW; Guba M
    Kidney Int; 2007 Jun; 71(12):1271-8. PubMed ID: 17332737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers.
    Cheung CY; Man Ma MK; Chak WL; Chau KF; Tang SCW
    Oncotarget; 2017 Jul; 8(27):44833-44841. PubMed ID: 28160552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of mTOR Inhibitors on Cancer Development in Kidney Transplantation Recipients: A Population-Based Study.
    Kao CC; Liu JS; Lin MH; Hsu CY; Chang FC; Lin YC; Chen HH; Chen TW; Hsu CC; Wu MS
    Transplant Proc; 2016 Apr; 48(3):900-4. PubMed ID: 27234763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
    Bachmann F; Glander P; Budde K; Bachmann C
    J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
    Bhat M; Watt KD
    Clin Transplant; 2015 Jul; 29(7):654-63. PubMed ID: 26094583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
    Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
    Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
    J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L; Kamar N
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Cervical Infection With Human Papillomavirus of High Oncogenic Potential in Immunosuppressed Women on Renal Replacement Therapy With and Without Mammalian Target of Rapamycin Inhibitors.
    Mazanowska N; Szpotańska-Sikorska M; Madej A; Pazik J; Wielgoś M; Pietrzak B
    Transplant Proc; 2018; 50(6):1889-1891. PubMed ID: 30056922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.
    Yanik EL; Siddiqui K; Engels EA
    Cancer Med; 2015 Sep; 4(9):1448-59. PubMed ID: 26108799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.